Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic oral chemotherapy regimens plus bevacizumab in advanced breast cancer
2005-005046-39Phase 2Completed
- Sponsor
- European Institute of Oncology
- Start
- Jan 2006
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab, cyclophosphamide, methotrexate and capecitabine in breast cancer (2 arms), sponsored by European Institute of Oncology. Primary endpoint: Overall clinical benefit. Started Jan 2006; status: completed.
02
Drugs
bevacizumabcyclophosphamidemethotrexatecapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-005046-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005046-39.